Scoop: Eli Lil­ly agrees to ac­quire an­oth­er Eu­ro­pean ADC biotech

Eli Lil­ly has agreed to ac­quire an­oth­er an­ti­body-drug con­ju­gate biotech, swoop­ing in for France-based Mablink Bio­science, End­points News has learned. The Sofinno­va-backed start­up is a part­ner of Emer­gence Ther­a­peu­tics, the oth­er Eu­ro­pean ADC biotech that Lil­ly bought ear­li­er this year.

It marks at least the sixth ac­qui­si­tion for Lil­ly in 2023, adding to its buys in di­a­betes, obe­si­ty, au­toim­mune dis­eases and ra­di­oli­gand ther­a­pies, though the com­pa­ny doesn’t al­ways dis­close small­er deals, chief sci­en­tif­ic of­fi­cer Dan Skovron­sky told End­points ear­li­er this week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER